Manufacturing / Pharmaceutical Preparations
PLIANT THERAPEUTICS, INC.
PLRX
$1.02
+$0.01 (+1.47%)
Price as of Oct 9, 2026 18:08 UTC
71 M
Market Cap (Micro Cap)
Nov 04
Next Earnings
Technical Signals
as of Oct 7
Bearish
1 of 7
Trend
- Above 20-day average $1.08
- Above 50-day average $1.10
- Above 200-day average $1.22 · -19.1%
- Moving averages stacked Not aligned
Momentum
- Golden cross (50/200) —
- Momentum cross (20/50) Down · 8d ago
Volume
- Elevated volume 2.1x avg
Price & Trend
Daily candles with EMA 20, SMA 50. Drag to zoom.
Options Heat Map
Delta-risk grid for PLRX options across strikes and expirations. Hover any cell for full Greeks.
Loading option chain data...
Insider Trades
0 buys
4 sells
| Date | Insider | Title | Type | Shares | Value | Since Trade |
|---|---|---|---|---|---|---|
| Oct 01, 2026 | Raben David | Grant | 575,000 | $0 | -4.8% | |
| Jul 09, 2026 | Iannone Robert | Grant | 60,000 | $0 | -11.5% | |
| Jul 09, 2026 | Borellini Flavia | Grant | 60,000 | $0 | -11.5% | |
| Jun 11, 2026 | MCCOURT Thomas A | Other | 70,000 | $0 | -12.3% | |
| Jun 11, 2026 | CROWELL GAYLE A | Other | 70,000 | $0 | -12.3% | |
| Jun 11, 2026 | Cline Darren S | Other | 70,000 | $0 | -12.3% | |
| Jun 11, 2026 | Cline Darren S | Grant | 70,000 | $0 | -12.3% | |
| Jun 11, 2026 | Curnutte John T | Grant | 70,000 | $0 | -12.3% | |
| Jun 11, 2026 | Huh Hoyoung | Grant | 70,000 | $0 | -12.3% | |
| Jun 11, 2026 | Krognes Steve E. | Grant | 70,000 | $0 | -12.3% |
Earnings History
| Date | Quarter | EPS Est. | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Aug 10, 2026 | Q2 2026 | -$0.35 | |||
| Aug 05, 2026 | Q2 2026 | -$0.35 | |||
| Mar 31, 2026 | Q1 2026 | -$0.36 | -$0.32 | +12.0% | Beat |
| Dec 31, 2025 | Q4 2025 | -$0.39 | -$0.38 | +1.5% | Beat |
| Sep 30, 2025 | Q3 2025 | -$0.53 | -$0.43 | +19.5% | Beat |
| Jun 30, 2025 | Q2 2025 | -$0.71 | -$0.71 | -0.1% | Miss |
| Mar 31, 2025 | Q1 2025 | -$0.74 | -$0.92 | -24.5% | Miss |
Track PLRX with ThetaPal
Get insider trade alerts, AI portfolio analysis, and options roll recommendations for PLRX and your entire portfolio.